Document Detail


Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins.
MedLine Citation:
PMID:  21838658     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The aim of the present paper is to address the legal aspects, technical requirements and possible conditions of use associated to low molecular weight heparin generics and biosimilars that are arriving to the market in United States and the European Union, respectively. To this end the concept of "similar biological medicinal product" that was coined in 2003 by the pharmaceutical legislation of the European Union is compared to the concept of generic in the United States and the concept of generic in the European Union. This different legal basis determines directly the technical requirements to obtain a marketing authorisation. Therefore, the chemical/biological, non-clinical and clinical requirements to demonstrate therapeutic equivalence are different in these two Regulatory Authorities, FDA and EMA. Consequently, the possible conditions of use are different. In the United States the products approved as generics by the FDA are considered interchangeable to the Reference Listed Drug. In contrast, the EMA legislation only deals with the approvability or prescribability of the medicines and it is a national / regional decision of the member States to consider these biosimilar products as interchangeable or not.
Authors:
Alfredo García-Arieta; Antonio Blázquez
Related Documents :
6526988 - The relationship of the level of training and area of medical specialization with regis...
11130938 - Advances in airway pharmacology. emerging trends and evolving controversy.
10802428 - Video analysis of emergency medicine residents performing rapid-sequence intubations.
7879358 - Emergencies of the female reproductive tract.
21328178 - Herbal medicines and infectious diseases: characterization by lc-spe-nmr of some medici...
8568438 - Human action and god's will: a problem of consistency in jewish bioethics.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-15
Journal Detail:
Title:  Current drug discovery technologies     Volume:  -     ISSN:  1875-6220     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-8-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101157212     Medline TA:  Curr Drug Discov Technol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
División de Farmacología y Evaluación Clínica, Subdirección de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain. ablazquez@aemps.es.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New Targets for Anticoagulation and Future Perspectives.
Next Document:  New Parenteral Anticoagulants: Focus on Factor Xa and Thrombin Inhibitors.